SEC Comment Letter 0000000000-24-008256 to Silo Pharma, Inc. (SILO)

Silo Pharma, Inc.
Date: July 22, 2024 · CIK: 0001514183 · Accession: 0000000000-24-008256

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-280855

Date

July 22, 2024

Author

Eric Weisblum

Form

UPLOAD

Company

Silo Pharma, Inc.

Letter

July 22, 2024 Eric Weisblum Chief Executive Officer Silo Pharma, Inc. 677 N. Washington Boulevard Sarasota, FL 34236 Re:Silo Pharma, Inc. Registration Statement on Form S-1 Filed July 17, 2024 File No. 333-280855 Dear Eric Weisblum: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Patrick Fullem at 202-551-8337 with any questions. Sincerely, Division of Corporation Finance Office of Manufacturing cc:Richard Friedman, Esq.

Show Raw Text

July 22, 2024
Eric Weisblum
Chief Executive Officer
Silo Pharma, Inc.
677 N. Washington Boulevard
Sarasota, FL 34236
Re:Silo Pharma, Inc.
Registration Statement on Form S-1
Filed July 17, 2024
File No. 333-280855
Dear Eric Weisblum:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Patrick Fullem at 202-551-8337 with any questions.
Sincerely,
Division of Corporation Finance
Office of Manufacturing
cc:Richard Friedman, Esq.

SecProbe.io